Completed PHASE3 INTERVENTIONAL NCT00002823

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer

A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Interventions cisplatin etoposide radiation therapy vinblastine sulfate vindesine vinorelbine tartrate

Updated 6 times since 2017 Last updated: Mar 26, 2013 Started: Feb 28, 1995 Primary completion: Jan 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Lung Cancer and is currently completed. Gustave Roussy, Cancer Campus, Grand Paris leads this study, which shows 6 recorded versions since 1995 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Angers, France , Armentières, France , Athens, Greece , Atlantis, United States , Aulnay-sous-Bois, France , Aurillac, France , Bagneux, France , Barcelona, Spain , Basel, Switzerland and 97 more locations